Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen
about
Argininosuccinate synthase: at the center of arginine metabolismPPARs and the cardiovascular systemPPAR-γ -- a possible drug target for complicated pregnanciesTime-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARγ)FXR-mediated regulation of eNOS expression in vascular endothelial cellsTwenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 diabetes?Regulation of obesity and insulin resistance by nitric oxideIn vitro and in vivo cytotoxicity of troglitazone in pancreatic cancerNovel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.Nitric Oxide Exerts Basal and Insulin-Dependent Anorexigenic Actions in POMC Hypothalamic Neurons.Salvia fruticosa Induces Vasorelaxation In Rat Isolated Thoracic Aorta: Role of the PI3K/Akt/eNOS/NO/cGMP Signaling Pathway.Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.Arsenite Acutely Decreases Nitric Oxide Production via the ROS-Protein Phosphatase 1-Endothelial Nitric Oxide Synthase-Thr(497) Signaling CascadeProtecting against vascular disease in brainRosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Endothelial cell dysfunction: can't live with it, how to live without it."Non alcoholic fatty liver disease and eNOS dysfunction in humans"Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblastsThe PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.Impact of obesity and insulin resistance on vasomotor tone: nitric oxide and beyond.Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.Functional Role of PPARs in Ruminants: Potential Targets for Fine-Tuning Metabolism during Growth and LactationVascular Actions of Angiotensin 1-7 in the Human Microcirculation: Novel Role for Telomerase.Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis.Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer.eNOS, metabolic syndrome and cardiovascular disease.Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.Endocannabinoids and the cardiovascular response to stress.Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.Regulation of eNOS enzyme activity by posttranslational modification.The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches
P2860
Q24620561-8AD16261-93B8-4DA1-BF33-5005A31BE196Q24642728-D798DAB3-46F3-49CE-AB4D-AF9189883B6DQ26863678-41DFECAF-59D3-4208-8B06-FA0329D8A1DDQ28243980-C525E1B6-F729-4BBE-A87D-B6EE3150B6F9Q28572543-2CC072C9-789B-4B45-8A3E-988A2D751BEBQ30352122-D2C73C52-F3CF-45B1-94FF-7528F4C76833Q30363035-0596A388-4324-41E0-97F4-5EC12BFE7236Q32174263-C195D40F-F9CF-4A20-9355-CB1798BCA465Q33401326-44E686C2-5A76-4940-9D70-7E2CA8198457Q33631400-4565C779-480D-425E-8F1D-C35EDD0DF12AQ33677627-14E60DFB-097B-4B6F-B77A-476B8794C0A5Q33746493-6960E119-4F0A-45A7-B9FA-0CD2DD935F1EQ34126249-CF455E69-00EA-4CE7-B103-62E5EF369BC5Q34620720-6504E6FB-D751-417C-9795-651781F1D253Q34632874-6C9A9913-73D2-4CF6-AF1C-697D02E1A1B3Q34979773-5F40D388-0C42-412A-86D0-3BA848302F20Q35608658-3668BA39-54D7-4625-9A02-DA8AAB61393DQ35688221-7C447C18-2A97-44F0-9C15-8F63D0D96BE6Q36093993-334EDF73-3751-4913-9B55-660346710413Q36298719-7E6E7DC5-380D-4F68-8B50-0020838928A5Q36320556-0F3CB630-E3A1-46AF-8A1D-14FD7ECD2556Q36417662-386B7A42-1495-48F9-80E2-3573CCE60C0AQ36445381-20A43920-EA43-44EE-89E4-649243B2C91BQ36478823-FD4107DF-301E-4089-A922-D6011881BEE2Q36632030-7A0FE06A-E236-4658-AD63-98C72AD31570Q36853537-A35A503F-B1BF-4393-A7E9-C03AE1D8BA4AQ36940666-2A6950EC-C041-42F2-9175-7569BD894148Q36964693-F3540841-ABD6-48CC-8E57-564FCA2A6DB0Q36972995-41370875-EFD1-45F7-8F86-E4F9B9317EE8Q37079967-C1AB2B7E-2B4B-4F34-B61F-60904BF30A66Q37157524-A3BF7CD7-C073-406D-8C88-A82746DDBD60Q37317509-FD8FE03E-C2B5-4E93-B54E-91E019B4E903Q37430999-97B0B328-05A8-4A68-8094-D1C2A1BF6562Q37894978-8DEB8179-665F-49B6-B8F8-7F178CB50715Q37943863-EC27BAA1-8F9A-4305-BC5A-E5E14486DD3AQ37992099-66998928-D8B1-4741-9A15-03F93B7A0BA8Q38158116-0F3E254C-652F-466D-B652-382779CB6D50Q38273378-BF9250E3-6EE5-4552-8E45-AF649BF36EF0Q41677812-F7390F06-7BE3-4CFE-9A80-25991371FBD1Q41938308-CA59A184-02A0-4DEC-A9E8-C6C3DF17929A
P2860
Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Nitric oxide production and re ...... ependent and PPARgamma-indepen
@en
Nitric oxide production and re ...... roliferator-activated receptor
@nl
type
label
Nitric oxide production and re ...... ependent and PPARgamma-indepen
@en
Nitric oxide production and re ...... roliferator-activated receptor
@nl
prefLabel
Nitric oxide production and re ...... ependent and PPARgamma-indepen
@en
Nitric oxide production and re ...... roliferator-activated receptor
@nl
P2093
P2860
P356
P1476
Nitric oxide production and re ...... ependent and PPARgamma-indepen
@en
P2093
Du-Hyong Cho
Sangmee Ahn Jo
Yoon Jung Choi
P2860
P304
P356
10.1074/JBC.M309451200
P407
P577
2003-10-30T00:00:00Z